Literature DB >> 22147672

2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician.

Nanette K Wenger1.   

Abstract

The 2011 Update to the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline is based in evolving data or expert opinion and incorporates information from late-breaking clinical trials presented at the 2008-2009 Scientific Sessions of the American College of Cardiology, the American Heart Association, and the European Society of Cardiology, among others, as well as selected data through April 2010. The 5 key issues highlighted in this summary are: (1) the timing of acute interventional therapy in non-ST-elevation myocardial infarction; (2) emphasis on the timing, duration, and application of dual and triple antiplatelet therapy; (3) specific recommendations for patients with diabetes mellitus; (4) the role and potential benefit of invasive therapy in patients with advanced renal dysfunction; and (5) issues of quality improvement for acute coronary syndromes.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147672      PMCID: PMC6652446          DOI: 10.1002/clc.20964

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  33 in total

Review 1.  Does hydration prevent radiocontrast-induced acute renal failure?

Authors:  C M Erley
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

2.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).

Authors:  James L Januzzi; Christopher P Cannon; Peter M DiBattiste; Sabina Murphy; William Weintraub; Eugene Braunwald
Journal:  Am J Cardiol       Date:  2002-12-01       Impact factor: 2.778

3.  Intensive insulin therapy in the medical ICU.

Authors:  Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

4.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

5.  Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose.

Authors:  Rosario V Freeman; Michael O'Donnell; David Share; William L Meengs; Eva Kline-Rogers; Vivian L Clark; Anthony C DeFranco; Kim A Eagle; John G McGinnity; Kirit Patel; Ann Maxwell-Eward; Diane Bondie; Mauro Moscucci
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Authors:  Gregg W Stone; Michel E Bertrand; Jeffrey W Moses; E Magnus Ohman; A Michael Lincoff; James H Ware; Stuart J Pocock; Brent T McLaurin; David A Cox; M Zubair Jafar; Harish Chandna; Franz Hartmann; Franz Leisch; Ruth H Strasser; Martin Desaga; Thomas D Stuckey; Richard B Zelman; Ira H Lieber; David J Cohen; Roxana Mehran; Harvey D White
Journal:  JAMA       Date:  2007-02-14       Impact factor: 56.272

7.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

8.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.

Authors:  Franz-Josef Neumann; Adnan Kastrati; Gisela Pogatsa-Murray; Julinda Mehilli; Hildegard Bollwein; Hans-Peter Bestehorn; Claus Schmitt; Melchior Seyfarth; Josef Dirschinger; Albert Schömig
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

9.  Acute myocardial infarction and renal dysfunction: a high-risk combination.

Authors:  R Scott Wright; Guy S Reeder; Charles A Herzog; Robert C Albright; Brent A Williams; David L Dvorak; Wayne L Miller; Joseph G Murphy; Stephen L Kopecky; Allan S Jaffe
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

10.  Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.

Authors:  Warren K Laskey; Charles Jenkins; Faith Selzer; Oscar C Marroquin; Robert L Wilensky; Ruchira Glaser; Howard A Cohen; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2007-07-30       Impact factor: 24.094

View more
  7 in total

Review 1.  The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

Authors:  Ping Wang; Shijie Zhou; Rui Zhou; Gan Liu; Ping Tang; Jing He; Cong Ma; Yi He; Jinliang Yang
Journal:  Clin Cardiol       Date:  2012-05-14       Impact factor: 2.882

2.  Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion.

Authors:  Scott J Cameron; Sara K Ture; Deanne Mickelsen; Enakshi Chakrabarti; Kristina L Modjeski; Scott McNitt; Michael Seaberry; David J Field; Nhat-Tu Le; Jun-Ichi Abe; Craig N Morrell
Journal:  Circulation       Date:  2015-05-01       Impact factor: 29.690

3.  Analysis of the CYP2C19 genetic polymorphism in Han and Uyghur patients with cardiovascular and cerebrovascular diseases in the Kashi area of Xinjiang.

Authors:  Yadong Li; Heyin Yang; Xiaoguang Zou; Lijun Xiong; Zhen Li; Jianzhang Luo; Bo Zhao; Wen Liu; Xili Du
Journal:  Med Sci Monit       Date:  2014-11-09

4.  Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction.

Authors:  Julie C Lauffenburger; Jennifer G Robinson; Christine Oramasionwu; Gang Fang
Journal:  Circulation       Date:  2013-12-10       Impact factor: 29.690

5.  Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion.

Authors:  Xiaoye Li; Shuning Zhang; Zi Wang; Qiuyi Ji; Qibing Wang; Xiaoyu Li; Qianzhou Lv
Journal:  Front Pharmacol       Date:  2019-10-09       Impact factor: 5.810

6.  Postoperative statin treatment may be associated with improved mortality in patients with myocardial injury after noncardiac surgery.

Authors:  Jungchan Park; Jihoon Kim; Seung-Hwa Lee; Jong Hwan Lee; Jeong Jin Min; Ji-Hye Kwon; Ah Ran Oh; Wonho Seo; Cheol Won Hyeon; Kwangmo Yang; Jin-Ho Choi; Sang-Chol Lee; Kyunga Kim; Joonghyun Ahn; Hyeon-Cheol Gwon
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

7.  Long noncoding RNA uc003pxg.1 regulates endothelial cell proliferation and migration via miR‑25‑5p in coronary artery disease.

Authors:  Ping Li; Yuan Li; Lu Chen; Xuexing Ma; Xinxin Yan; Meina Yan; Buyun Qian; Feng Wang; Jingyi Xu; Juan Yin; Guidong Xu; Kangyun Sun
Journal:  Int J Mol Med       Date:  2021-07-02       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.